Host-Guest Complexation of Oxaliplatin and Para-Sulfonatocalix[n]Arenes for Potential Use in Cancer Therapy
Abstract
:1. Introduction
2. Experimental and Computational Studies
2.1. Chemicals and Reagents
2.2. Instrumentation
2.3. Construction of Calibration Graphs (DD1 Method)
2.4. Cell Viability Assay
Sulforhodamine B Colorimetric Assay (SRB)
2.5. Computational Details
3. Results
3.1. H NMR Spectroscopy
3.2. UV-Vis Spectroscopy
3.3. In Vitro Cell Viability Assay
3.4. Computational Results
3.4.1. DFT Calculations
3.4.2. ADMET Studies
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Ritacco, I.; Al Assy, M.; Abd El-Rahman, M.K.; Fahmy, S.A.; Russo, N.; Shoeib, T.; Sicilia, E. Hydrolysis in Acidic Environment and Degradation of Satraplatin: A Joint Experimental and Theoretical Investigation. Inorg. Chem. 2017, 56, 6013–6026. [Google Scholar] [CrossRef] [PubMed]
- Harper, B.W.; Krause-Heuer, A.M.; Grant, M.P.; Manohar, M.; Garbutcheon-Singh, K.B.; Aldrich-Wright, J.R. Advances in platinum chemotherapeutics. Chem. A Eur. J. 2010, 16, 7064–7077. [Google Scholar] [CrossRef] [PubMed]
- Wong, E.; Giandomenico, C.M. Current Status of Platinum-Based Antitumor Drugs. Chem. Rev. 1999, 99, 2451–2466. [Google Scholar] [CrossRef]
- Jakupec, M.A.; Galanski, M.; Keppler, B.K. Tumour-inhibiting platinum complexes-state of the art and future perspectives. Rev. Physiol. Biochem. Pharmacol. 2003, 146, 1–54. [Google Scholar] [PubMed]
- Wheate, N.J.; Walker, S.; Craig, G.E.; Craig, G.E.; Oun, R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010, 39, 8113–8127. [Google Scholar] [CrossRef] [Green Version]
- Arango, D.; Wilson, A.J.; Shi, Q.; Corner, G.A.; Arañes, M.J.; Nicholas, C.; Lesser, M.; Mariadason, J.M.; Augenlicht, L.H. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br. J. Cancer 2004, 91, 1931–1946. [Google Scholar] [CrossRef] [Green Version]
- Boulikas, T.; Pantos, A.; Bellis, E.; Christofis, P. Designing platinum compounds in cancer: Structures and mechanisms (review). Cancer Therapy 2007, 5, 537–583. [Google Scholar]
- Alcindor, T.; Beauger, N. Oxaliplatin: A review in the era of molecularly targeted therapy. Curr. Oncol. 2011, 18, 18–25. [Google Scholar] [CrossRef] [Green Version]
- Scheeff, E.D.; Briggs, J.M.; Howell, S.B. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol. Pharmacol. 1999, 56, 633–643. [Google Scholar] [CrossRef]
- Messori, L.; Marzo, T.; Merlino, A. Protein metalation by metal-based drugs: X-ray crystallography and mass spectrometry studies. J. Inorg. Biochem. 2015, 153, 136–142. [Google Scholar] [CrossRef]
- Sciortino, G.; Sánchez-Aparicio, J.E.; Rodríguez-Guerra Pedregal, J.; Garribba, E.; Maréchal, J.D. Computational insight into the interaction of oxaliplatin with insulin. Metallomics 2019, 11, 765–773. [Google Scholar] [CrossRef] [PubMed]
- Kweekel, D.; Gelderblom, H.; Guchelaar, H. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat. Rev. 2005, 31, 90–105. [Google Scholar] [CrossRef] [PubMed]
- Zhang, S.; Katherine, S.; Lovejoy, J.E.; Shima, L.L.; Lagpacan, Y.S.; Lapuk, A.; Chen, Y.; Komori, T.; Gray, J.W.; Chen, X.; et al. Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity. Cancer Res. 2006, 66, 8847–8857. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bokemeyer, C.; Kollmannsberger, C.; Harstrick, A.; Beyer, J.; Gerl, A.; Casper, J.; Metzner, B.; Hartmann, J.T.; Clemm, C.; Schmoll, H.-J.; et al. Treatment of patients with cisplatin-refractory testicular germ-cell cancer. Int. J. Cancer 1999, 83, 848–851. [Google Scholar] [CrossRef]
- Stordal, B.; Pavlakis, N.; Davey, R. Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review. Cancer Treat. Rev. 2007, 33, 347–357. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lévi, F.; Metzger, G.; Massari, C.; Milano, G. Oxaliplatin: Pharmacokinetics and Chronopharmacological Aspects. Clin. Pharmacokinet. 2000, 38, 1–21. [Google Scholar] [PubMed]
- Montagnani, F.; Turrisi, G.; Marinozzi, C.; Aliberti, C.; Fiorentini, G. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: A systematic review and meta-analysis. Gastric Cancer 2011, 14, 50–55. [Google Scholar] [CrossRef] [Green Version]
- Dragovich, T.; Mendelson, D.; Kurtin, S.; Richardson, K.; Von Hoff, D.; Hoos, A. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother. Pharmacol. 2006, 58, 759–764. [Google Scholar] [CrossRef]
- Lu, C.; Perez-Soler, R.; Piperdi, B.; Walsh, G.L.; Swisher, S.G.; Smythe, W.R.; Shin, H.J.; Ro, J.; Feng, L.; Truong, M.; et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2005, 23, 3495–3501. [Google Scholar] [CrossRef]
- El-Shafie, S.; Fahmy, S.A.; Ziko, L.; Elzahed, N.; Shoeib, T.; Kakarougkas, A. Encapsulation of Nedaplatin in Novel PEGylated Liposomes Increases Its Cytotoxicity and Genotoxicity against A549 and U2OS Human Cancer Cells. Pharmaceutics 2020, 12, 863. [Google Scholar] [CrossRef]
- Fahmy, S.A.; Mamdouh, W. Garlic oil–loaded PLGA nanoparticles with controllable size and shape and enhanced antibacterial activities. J. Appl. Polym. Sci. 2018, 135. [Google Scholar] [CrossRef]
- Koshkaryev, A.; Sawant, R.; Deshpande, M.; Torchilin, V. Immunoconjugates and long circulating systems: Origins, current state of the art and future directions. Adv. Drug Deliv. Rev. 2013, 65, 24–35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alexis, F.; Pridgen, E.M.; Langer, R.; Farokhzad, O.C. Nanoparticle Technologies for Cancer Therapy. In Drug Delivery. Handbook of Experimental Pharmacology; Schäfer-Korting, M., Ed.; Springer: Berlin/Heidelberg, Germany, 2010; Volume 197. [Google Scholar]
- Haag, R. Supramolecular Drug-Delivery Systems Based on Polymeric Core–Shell. Architectures. Angew. Chem. Int. Ed. 2004, 43, 278–282. [Google Scholar] [CrossRef] [PubMed]
- Loh, X.J. Supramolecular host–guest polymeric materials for biomedical applications. Mater. Horiz. 2014, 1, 185–195. [Google Scholar] [CrossRef]
- Fahmy, S.A.; Brüßler, J.; Alawak, M.; El-Sayed, M.M.H.; Bakowsky, U.; Shoeib, T. Chemotherapy Based on Supramolecular Chemistry: A Promising Strategy in Cancer Therapy. Pharmaceutics 2019, 11, 292. [Google Scholar] [CrossRef] [Green Version]
- Cao, L.; Hettiarachchi, G.; Briken, V.; Isaacs, L. Cucurbit[7]uril containers for targeted delivery of oxaliplatin to cancer cells. Angew. Chem. 2013, 52, 12033–12037. [Google Scholar] [CrossRef] [Green Version]
- Chen, Y.; Huang, Z.; Zhao, H.; Xu, J.-F.; Sun, Z.; Zhang, X. Supramolecular Chemotherapy: Cooperative Enhancement of Antitumor Activity by Combining Controlled Release of Oxaliplatin and Consuming of Spermine by Cucurbit[7]uril. ACS Appl. Mater. Interfaces 2017, 9, 8602–8608. [Google Scholar] [CrossRef] [Green Version]
- Jeon, Y.J.; Kim, S.Y.; Ko, Y.H.; Sakamoto, S.; Yamaguchi, K.; Kim, K. Novel molecular drug carrier: Encapsulation of oxaliplatin in cucurbit[7]uril and its effects on stability and reactivity of the drug. Org. Biomol. Chem. 2005, 3, 2122–2125. [Google Scholar] [CrossRef] [Green Version]
- Plumb, J.A.; Venugopal, B.; Oun, R.; Gomez-Roman, N.; Kawazoe, Y.; Venkataramanan, N.S.; Wheate, N.J. Cucurbit[7]uril encapsulated cisplatin overcomes cisplatin resistance via a pharmacokinetic effect. Met. Integr. Biometal Sci. 2012, 4, 561–567. [Google Scholar] [CrossRef] [Green Version]
- Fahmy, S.A.; Ponte, F.; Abd El-Rahman, M.K.; Russo, N.; Sicilia, E.; Shoeib, T. Investigation of the host-guest complexation between 4-sulfocalix[4]arene and nedaplatin for potential use in drug delivery. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2018, 193, 528–536. [Google Scholar] [CrossRef]
- El-Rahman, M.K.A.; Mahmoud, A.M. A novel approach for spectrophotometric determination of succinylcholine in pharmaceutical formulation via host–guest complexation with water-soluble p-sulfonatocalixarene. RSC Adv. 2015, 5, 62469. [Google Scholar] [CrossRef]
- Joyce, L.A.; Shabbir, S.H.; Anslyn, E.V. The uses of supramolecular chemistry in synthetic methodology development: Examples of anion and neutral molecular recognition. Chem. Soc. Rev. 2010, 39, 3621–3632. [Google Scholar] [CrossRef] [PubMed]
- Strobel, M.; Kita-Tokarczyk, K.; Taubert, A. Self-Assembly of Amphiphilic Calix[4]arenes in Aqueous Solution. Adv. Funct. Mater. 2006, 16, 252–259. [Google Scholar] [CrossRef]
- Trush, V.V.; Cherenok, S.O.; Tanchuk, V.Y.V.; Viacheslav, V.; Trush, S.O.; Cherenok, V.Y.; Tanchuk, V.P.K.; Kalchenko, V.I.; Vovk, A.I. Calix[4]arene methylenebisphosphonic acids as inhibitors of protein tyrosine phosphatase 1B. Bioorg. Med. Chem. Lett. 2013, 23, 5619–5623. [Google Scholar] [CrossRef]
- NasuhiPur, F.; Dilmaghani, K.A. Calixplatin: Novel potential anticancer agent based on the platinum complex with functionalized calixarene. J. Coord. Chem. 2014, 67, 440–448. [Google Scholar] [CrossRef]
- Hulíková, K.; Grobárová, V.; Křivohlavá, R.; Fišerová, A. Antitumor activity of N-acetyl-d-glucosamine-substituted glycoconjugates and combined therapy with keyhole limpet hemocyanin in B16F10 mouse melanoma model. Folia Microbiol. 2010, 55, 528–532. [Google Scholar] [CrossRef]
- Cherenok, S.O.; Yushchenko, O.A.; Tanchuk, V.Y.; Mischenko, I.M.; Samus, N.V.; Ruban, O.V.; Matvieiev, Y.I.; Karpenko, J.A.; Kukhar, V.P.; Vovk, A.I.; et al. Calix[4]arene-α-hydroxyphosphonic acids. Synthesis, stereochemistry, and inhibition of glutathione S-transferase. ARKIVOC 2012, 4, 278–298. [Google Scholar] [CrossRef]
- Cherenok, S.; Vovk, A.; Muravyova, I.; Shivanyuk, A.; Kukhar, V.; Lipkowski, J.; Kalchenko, V. Calix[4]arene α-Aminophosphonic Acids: Asymmetric Synthesis and Enantioselective Inhibition of an Alkaline Phosphatase. Org. Lett. 2006, 8, 549–552. [Google Scholar] [CrossRef]
- Grazia, M.L.; Consoli, G.G.; Galante, E.; Di Silvestro, I.; Salafia, L.; Geraci, C. Synthesis of water-soluble nucleotide-calixarene conjugates and preliminary investigation of their in vitro DNA replication inhibitory activity. Tetrahedron 2007, 63, 10758–10763. [Google Scholar]
- Zhou, H.; Wang, D.A.; Baldini, L.; Ennis, E.; Jain, R.; Carie, A.; Sebti, S.M.; Hamilton, A.M. Structure–activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation. Org. Biomol. Chem. 2006, 4, 2376–2386. [Google Scholar] [CrossRef]
- Dings, R.P.M.; Chen, X.; Hellebrekers, D.M.E.I.; van Eijk, L.I.; Zhang, Y.; Hoye, T.R.; Griffioen, A.W.; Mayo, K.H. Design of Nonpeptidic Topomimetics of Antiangiogenic Proteins With Antitumor Activities. J. Natl. Cancer Inst. 2006, 98, 932–936. [Google Scholar] [CrossRef] [PubMed]
- Dings, R.P.M.; Levine, J.I.; Brown, S.G.; Astorgues-Xerri, L.; MacDonald, J.R.; Hoye, T.R.; Raymond, E.; Mayo, K.H. Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. Investig. New Drugs. 2013, 31, 1142–1150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kamada, R.; Yoshino, W.; Nomura, T.; Chuman, Y.; Imagawa, T.; Suzuki, T.; Sakaguchi, K. Enhancement of transcriptional activity of mutant p53 tumor suppressor protein through stabilization of tetramer formation by calix[6]arene derivatives. Bioorg. Med. Chem. Lett. 2010, 20, 4412–4415. [Google Scholar] [CrossRef] [PubMed]
- Pelizzaro-Rocha, K.J.; de Jesus, M.B.; Ruela-de-Sousa, R.R.; Nakamura, C.V.; Reis, F.S.; de Fátima, A.; Ferreira-Halder, C.V. Calix[6]arene bypasses human pancreatic cancer aggressiveness: Downregulation of receptor tyrosine kinases and induction of cell death by reticulum stress and autophagy. BBA-Mol. Cell. Res. 2013, 1833, 2856–2865. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schrama, D.; Reisfeld, R.A.; Becker, J.C. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 2006, 5, 147–159. [Google Scholar] [CrossRef]
- Geraci, C.; Consoli, G.M.L.; Granata, G.; Galante, E.; Palmigiano, A.; Pappalardo, M.; Di Puma, S.D.; Spadaro, A. First Self-Adjuvant Multicomponent Potential Vaccine Candidates by Tethering of Four or Eight MUC1 Antigenic Immunodominant PDTRP Units on a Calixarene Platform: Synthesis and Biological Evaluation. Bioconjug. Chem. 2013, 24, 1710–1720. [Google Scholar] [CrossRef] [PubMed]
- Brown, S.D.; Plumb, J.A.; Johnston, B.F.; Wheate, N.J. Folding of dinuclear platinum anticancer complexes within the cavity of para-sulphonatocalix[4]arene. Inorg. Chim. Acta. 2012, 393, 182–186. [Google Scholar] [CrossRef]
- Gutsche, C.D.; Bauer, L.J. Calixarenes. 13. The conformational properties of calix[4]arenes, calix[6]arenes, calix[8]arenes, and oxacalixarenes. J. Am. Chem. Soc. 1985, 107, 6052–6059. [Google Scholar] [CrossRef]
- Guo, D.S.; Liu, Y.J. Supramolecular Chemistry of p-Sulfonatocalix[n]arenes and Its Biological Applications. J. Chem. Res. 2014, 47, 1925–1934. [Google Scholar] [CrossRef]
- Coleman, A.W.; Jebors, S.; Cecillon, S.; Perret, P.; Garin, D.; Marti-Battle, D.; Moulin, M. Toxicity and biodistribution of para-sulfonato-calix[4]arene in mice. New J. Chem. 2008, 32, 780–782. [Google Scholar] [CrossRef]
- Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistiga, D.; Warren, T.J.; Bokesch, H.; Kenney, S.; Boyd, M.R. New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening. J. Natl. Cancer Inst. 1990, 82, 1107–1112. [Google Scholar] [CrossRef]
- Allam, R.M.; Al-Abd, A.M.; Khedr, A.; Sharaf, O.A.; Nofal, S.M.; Khalifa, A.E.; Mosli, H.A.; Abdel-Naim, A.B. Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells. Toxicol. Lett. 2018, 291, 77–85. [Google Scholar] [CrossRef]
- Vichai, V.; Kirtikara, K.S. ulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 2006, 1, 1112–1116. [Google Scholar] [CrossRef]
- Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheseman, J.R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G.A. Gaussian 09, Revision A.02, Revision D.01; Gaussian, Inc.: Wallingford, CT, USA, 2009. [Google Scholar]
- Andrae, D.; Häusermann, U.; Dolg, M.; Stoll, H.; Preuss, H. Energy-adjusted ab initio pseudopotentials for the second and third row transition elements. Theor. Chim. Acta 1990, 77, 123. [Google Scholar] [CrossRef]
- El-Rahman, M.K.; Mazzone, G.; Mahmoud, A.M.; Sicilia, E.; Shoeib, T. Spectrophotometric determination of choline in pharmaceutical formulations via host-guest complextaion with a biomimetic calixarene receptor. Microchem. J. 2019, 146, 735–741. [Google Scholar] [CrossRef]
- Cossi, M.; Barone, V. Solvent effect on vertical electronic transitions by the polarizable continuum model. J. Chem. Phys. 2000, 112, 2427–2435. [Google Scholar] [CrossRef]
- Boys, S.F.; Bernardi, F. The calculation of small molecular interactions by the differences of separate total energies. Mol. Phys. 1970, 19, 553. [Google Scholar] [CrossRef]
- Guex, N.; Peitsch, M.C. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 1997, 18, 2714–2723, Ver. 4.1.0. Available online: http://www.expasy.org/spdbv/ (accessed on 28 November 2020). [CrossRef]
- Wheate, N.J. Improving platinum(II)-based anticancer drug delivery using cucurbit[n]urils. J. Inorg. Biochem. 2008, 102, 2060–2066. [Google Scholar] [CrossRef]
- Wheate, N.J.; Abbott, G.M.; Tate, R.J.; Clements, C.J.; Edrada-Ebel, R.; Johnston, B.F. Side-on binding of p-sulphonatocalix[4]arene to the dinuclear platinum complex trans-[{PtCl(NH3)2}2mu-dpzm]2+ and its implications for anticancer drug delivery. J. Inorg. Biochem. 2009, 103, 448–454. [Google Scholar] [CrossRef]
- Guo, D.-S.; Uzunova, V.D.; Su, X.; Liu, Y.; Nau, W.M. Operational calixarene-based fluorescent sensing systems for choline and acetylcholine and their application to enzymatic reactions. Chem. Sci. 2011, 2, 1722. [Google Scholar] [CrossRef]
- Shinkai, S.; Araki, K.; Matsuda, T.; Manabe, O. NMR Determination of Association Constants for Aqueous Calixarene Complexes and Guest Template Effects on the Conformational Freedom. Bull. Chem. Soc. Jpn. 1989, 62, 3856–3862. [Google Scholar] [CrossRef] [Green Version]
- Shinkai, K.; Araki, O.; Manabe, S. NMR determination of association constants for calixarene complexes. Evidence for the formation of a 1:2 complex with calix[8]arene. J. Am. Chem. Soc. 1998, 110, 7214–7215. [Google Scholar] [CrossRef]
- Fahmy, S.A.; Ponte, F.; Sicilia, E.; Azzazy, H.M.E.-S. Experimental and Computational Investigations of Carboplatin Supramolecular Complexes. ACS Omega 2020, 5, 31456–31466. [Google Scholar] [CrossRef]
- Olson, E.J.; Buhlmann, P. Getting More out of a Job Plot: Determination of Reactant to Product Stoichiometry in Cases of Displacement Reactions and n:n Complex Formation. J. Org. Chem. 2011, 76, 8406. [Google Scholar] [CrossRef]
- Salem, M.Y.; El-Kosasy, A.M.; El-Bardicy, M.G.; Abd El-Rahman, M.K. Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product. Drug Test. Anal. 2010, 2, 225. [Google Scholar] [CrossRef]
- Darwish, H.W.; Hassan, S.A.; Salem, M.Y.; El-Zeany, A.B. Comparative study between derivative spectrophotometry and multivariate calibration as analytical tools applied for the simultaneous quantitation of Amlodipine, Valsartan and Hydrochlorothiazide. Spectrochim. Acta A Mol.Biomol. Spectrosc. 2013, 113, 215. [Google Scholar] [CrossRef]
- Nebsen, M.; Abd El-Rahman, M.K.; Salem, M.Y.; El-Kosasy, A.M.; El-Bardicy, M.G. Stability-indicating spectrophotometric and spectrodensitometric methods for the determination of diacerein in the presence of its degradation product. Drug Test. Anal. 2011, 3, 221. [Google Scholar] [CrossRef]
- Bosque-Sendra, J.M.; Almansa-López, E.; García-Campaña, A.M.; Cuadros- Rodríguez, L. Data Analysis in the Determination of Stoichiometries and Stability Constants of Complexes. Anal. Sci. 2003, 19, 1431. [Google Scholar] [CrossRef] [Green Version]
- Carvalho, C.P.; Uzunova, V.D.; Da Silva, J.P.; Nau, W.M.; Pischel, U. A photoinduced pH jump applied to drug release from cucurbit[7]uril. Chem. Commun. 2011, 47, 8793–8795. [Google Scholar] [CrossRef] [Green Version]
- Marquez, C.; Nau, W.M. Two Mechanisms of Slow Host-Guest Complexation between Cucurbit[6]uril and Cyclohexylmethylamine: pH-Responsive Supramolecular Kinetics. Angew. Chem. Int. Ed. 2001, 40, 3155–3160. [Google Scholar] [CrossRef]
- Miskolczy, Z.; Biczok, L. Photochromism in Cucurbit[8]uril Cavity: Inhibition of Hydrolysis and Modification of the Rate of Merocyanine–Spiropyran Transformations. J. Phys. Chem. B 2011, 115, 12577–12583. [Google Scholar] [CrossRef] [PubMed]
- Wu, J.; Isaacs, L. Cucurbit[7Cao]uril Complexation Drives Thermal trans–cis-Azobenzene Isomerization and Enables Colorimetric Amine Detection. Chem. Eur. J. 2009, 15, 11675–11680. [Google Scholar] [CrossRef] [PubMed]
- Pischel, U.; Uzunova, V.D.; Remon, P.; Nau, W.M. Supramolecular logic with macrocyclic input and competitive reset. Chem. Commun. 2010, 46, 2635–2637. [Google Scholar] [CrossRef]
- Praetorius, A.; Bailey, D.M.; Schwarzlose, T.; Nau, W.M. Design of a Fluorescent Dye for Indicator Displacement from Cucurbiturils: A Macrocycle-Responsive Fluorescent Switch Operating through a pKa Shift. Org. Lett. 2008, 10, 4089–4092. [Google Scholar] [CrossRef]
- Koner, A.L.; Nau, W.M. Cucurbituril Encapsulation of Fluorescent Dyes. Supramol. Chem. 2007, 19, 55–66. [Google Scholar] [CrossRef] [Green Version]
- Arantes, L.M.; Varejao, E.V.; Pelizzaro-Rocha, K.J.; Cereda, C.M.; de Paula, E.; Lourenco, M.P.; Duarte, H.A.; Fernandes, S.A. Benzocaine Complexation with p-Sulfonic Acid Calix[n]arene: Experimental (1H-NMR) and Theoretical Approaches. Chem. Biol. Drug Des. 2014, 83, 550–559. [Google Scholar] [CrossRef] [Green Version]
- Shaikh, M.; Mohanty, P.K.J.; Singh, W.M.; Nau, P.H. Complexation of acridine orange by cucurbit[7]uril and β-cyclodextrin: Photophysical effects and pKa shifts. Photobiol. Sci. 2008, 7, 408–414. [Google Scholar] [CrossRef]
- Bakirci, H.; Koner, A.; Schwarzlose, T.; Nau, M.W. Analysis of host-assisted guest protonation exemplified for p-sulfonatocalix[4]arene—Towards enzyme-mimetic pKa shifts. Chem. Eur. J. 2006, 12, 4799–4807. [Google Scholar] [CrossRef]
- Wang, G.; Zhang, H.; Ding, F.; Liu, Y. Preparation and characterization of inclusion complexes of topotecan with sulfonatocalixarene. Macrocycl. Chem. 2011, 69, 85–89. [Google Scholar] [CrossRef]
- Yang, W.; de Villiers, M.; Yang, W.; De Villiers, M. Effect of 4-Sulphonato-Calix[n]Arenes and Cyclodextrins on the Solubilizationof Niclosamide, a Poorly Water Soluble Anthelmintic. AAPS J. 2005, 7, 23. Available online: http://www.aapsj.org (accessed on 28 November 2020). [CrossRef] [PubMed] [Green Version]
- Zhang, D.; Zhang, J.; Jiang, K.; Li, K.; Cong, Y.; Pu, S.; Jin, Y.; Lin, J. Preparation, characterisation and antitumour activity of β-, γ-and HP-β-cyclodextrin inclusion complexes of oxaliplatin. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 2016, 152, 501–508. [Google Scholar] [CrossRef] [PubMed]
- Fahmy, S.A.; Brüßler, J.; Ponte, F.; Abd El-Rahman, M.K.; Russo, N.; Sicilia, E.; Bakowsky, U.; Shoeib, T. A study on the physicochemical properties and cytotoxic activity of p-sulfocalix[4]arene-nedaplatin complex. J. Phys. Conf. Ser. 2019, 1310. [Google Scholar] [CrossRef]
- Yousaf, A.; Hamid, S.A.; Bunnori, N.M.; Ishola, A.A. Applications of calixarenes in cancer chemotherapy: Facts and perspectives. Drug Des. Devel. Ther. 2015, 9, 2831–2838. [Google Scholar] [PubMed] [Green Version]
- Dennington, R.; Keith, T.; Millam, J. (Eds.) GaussView; Version 6.1.1; Semichem Inc.: Shawnee Mission, KS, USA, 2019. [Google Scholar]
Proton Signals | Individual Molecules | 1:1 Molar Ratio |
---|---|---|
3ax | 0.92–1.00 | 0.19–0.25 |
2ax | 1.16–1.25 | 0.38–0.44 |
3eq | 1.39–1.46 | 0.98–1.04 |
2eq | 1.81–1.88 | 1.16–1.21 |
1 | 2.03–2.04 | 1.63–1.66 |
Hy | 3.67 | 3.83 |
Cells | In Vitro Anticancer Activity (IC50 in µg/mL) | ||||
---|---|---|---|---|---|
p-SC4 | p-SC6 | Oxaliplatin | Oxaliplatin/p-SC4 | Oxaliplatin/p-SC6 | |
HT-29 | N/A | 10 | 3.9 | 2 | 1.3 |
MCF-7 | N/A | 220 | 5 | 1.56 | 0.59 |
Sample Availability: Samples of the compounds are not available from the authors. |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Fahmy, S.A.; Ponte, F.; Fawzy, I.M.; Sicilia, E.; Bakowsky, U.; Azzazy, H.M.E.-S. Host-Guest Complexation of Oxaliplatin and Para-Sulfonatocalix[n]Arenes for Potential Use in Cancer Therapy. Molecules 2020, 25, 5926. https://doi.org/10.3390/molecules25245926
Fahmy SA, Ponte F, Fawzy IM, Sicilia E, Bakowsky U, Azzazy HME-S. Host-Guest Complexation of Oxaliplatin and Para-Sulfonatocalix[n]Arenes for Potential Use in Cancer Therapy. Molecules. 2020; 25(24):5926. https://doi.org/10.3390/molecules25245926
Chicago/Turabian StyleFahmy, Sherif Ashraf, Fortuna Ponte, Iten M. Fawzy, Emilia Sicilia, Udo Bakowsky, and Hassan Mohamed El-Said Azzazy. 2020. "Host-Guest Complexation of Oxaliplatin and Para-Sulfonatocalix[n]Arenes for Potential Use in Cancer Therapy" Molecules 25, no. 24: 5926. https://doi.org/10.3390/molecules25245926